Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The Mutational Landscape of Prostate Cancer

Open access
Barbieri, Christopher E., Bangma, Chris H., Bjartell, Anders, Catto, James W.F., Culig, Zoran, Grönberg, Henrik, Luo, Jun, Visakorpi, Tapio, Rubin, Mark A.·2013·European Urology

Abstract

Context Prostate cancer is a clinically heterogeneous disease with marked variability in patient outcomes. Molecular characterization has revealed striking mutational heterogeneity that may underlie the variable clinical course of the disease. Objective In this review, we discuss the common genomic alterations that form the molecular basis of prostate cancer, their functional significance, and potential to translate this knowledge toward patient care. Evidence Acquisition We reviewed the relevant literature, with a particular focus on recent studies on somatic alterations in prostate cancer. Evidence Synthesis Advances in sequencing technology have resulted in an explosion of data regarding the mutational events underlying the development and progression of prostate cancer. Heterogeneity is the norm; few abnormalities in specific genes are highly recurrent, but alterations in certain signaling pathways do predominate. These include pathways known to affect tumorigenesis in a wide spectrum of tissues, such as PI3K/PTEN/AKT, cell cycle regulation, and chromatin regulation. Alterations more specific to prostate cancer are also observed, particularly gene fusions of ETS transcription factors and alterations in androgen signaling. Mounting data suggests that prostate cancer can be subdivided based on a molecular profile of genetic alterations. Conclusions Major advances have been made in cataloguing the genomic alterations in prostate cancer and understanding the molecular mechanisms underlying the disease. These findings raise the possibility that prostate cancer could soon transition from a poorly understood, heterogeneous disease with a variable clinical course to a collection of homogenous subtypes, identifiable by molecular criteria, associated with distinct risk profiles, and perhaps amenable to specific management strategies or targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2013.05.029

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 239

Metadata

Authors
Barbieri, C. E., Bangma, C. H., Bjartell, A., Catto, J. W. F., Culig, Z., Grönberg, H., Luo, J., Visakorpi, T., & Rubin, M. A.
Venue
European Urology
Publisher
Elsevier BV
Published
2013-10
Volume
64
Issue
4
Pages
567-576
ISSN
0302-2838 (ISSN-L)
OpenAlex
W1968302410
Cited by
239
References
6
FWCI
22.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Mutational Landscape of Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2013.05.029
The paper
Barbieri, C. E., Bangma, C. H., Bjartell, A., Catto, J. W. F., Culig, Z., Grönberg, H., Luo, J., Visakorpi, T., & Rubin, M. A. (2013). The Mutational Landscape of Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2013.05.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.